title: The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness.
abstract: OBJECTIVE
  To compare the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness (CCT).
  
  
  METHODS
  A total of 69 eyes of 69 patients with glaucoma or ocular hypertension submitted to monotherapy with prostaglandin analogues (latanoprost 0.005%, travoprost 0.004%, or bimatoprost 0.03%) during a mean of 17.19 ± 15.71 months follow-up period. Measurements were performed at the initial diagnosis and at the end of follow-up. All the measurements were carried out by the same doctor between 9 am and 11 am, using Goldmann applanation tonometer for intraocular pressure and ultrasonic pachymetry for CCT.
  
  
  RESULTS
  A statistically significant reduction in CCT was observed in all groups (P < 0.001). The reduction of CCT in the latanoprost, travoprost, and bimatoprost groups was 14.95 ± 5.04, 15.73 ± 3.25, and 17.00 ± 6.23 μm, respectively. No significant difference was found in the reduction of CCT among the 3 groups (P > 0.05). No significant difference was also found in the reduction of CCT between the patients with less than or equal to 6 months' treatment and the patients with more than 6 months' treatment in the 3 groups (P > 0.05).
  
  
  CONCLUSIONS
  Topical therapy with prostaglandin analogues is associated with CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar effect on CCT.
authors.affiliation: Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, Shanghai, China. yszhong68@yahoo.com.cn
authors.forename: Yisheng
authors.initials: Y
authors.lastname: Zhong
authors.forename: Xi
authors.initials: X
authors.lastname: Shen
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.forename: Haibo
authors.initials: H
authors.lastname: Tan
authors.forename: Yu
authors.initials: Y
authors.lastname: Cheng
mesh_terms: D000287:Administration, Topical; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069580:Bimatoprost; D001837:Body Weights and Measures; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003315:Cornea / Q000000981:diagnostic imaging / Q000187:drug effects*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use; D014065:Tonometry, Ocular; D000069557:Travoprost; D014463:Ultrasonography
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost